{"filing":{"accession_number":"0001213900-26-071804","cik":"0001681682","ticker":"NDRA","company_name":"ENDRA Life Sciences Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"ea0295899-8k425_endra.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/ea0295899-8k425_endra.htm"},"events":[{"id":13781,"run_id":12242,"accession_number":"0001213900-26-071804","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses a proposed merger of ENDRA's subsidiary with Noble Africa LLC (a wholly-owned subsidiary of ASP Isotopes), with Noble Africa as the surviving entity. The transaction is expected to close in Q3 or Q4 2026 and includes a concurrent $50 million private placement financing. This is a material acquisition/change of control event that would substantially affect ENDRA's stockholders, who are expected to own approximately 3% of the combined company post-closing, with ASP Isotopes owning ~89%.","company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11020,"accession_number":"0001213900-26-071804","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a proposed merger of ENDRA's subsidiary with Noble Africa LLC (a wholly-owned subsidiary of ASP Isotopes), with Noble Africa as the surviving entity. The transaction is expected to close in Q3 or Q4 2026 and includes a concurrent $50 million private placement financing. This is a material acquisition/change of control event that would substantially affect ENDRA's stockholders, who are expected to own approximately 3% of the combined company post-closing, with ASP Isotopes owning ~89%.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T13:37:44.227292+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11020,"accession_number":"0001213900-26-071804","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a proposed merger of ENDRA's subsidiary with Noble Africa LLC (a wholly-owned subsidiary of ASP Isotopes), with Noble Africa as the surviving entity. The transaction is expected to close in Q3 or Q4 2026 and includes a concurrent $50 million private placement financing. This is a material acquisition/change of control event that would substantially affect ENDRA's stockholders, who are expected to own approximately 3% of the combined company post-closing, with ASP Isotopes owning ~89%.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T13:37:44.227292+00:00","company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","filing_date":"2026-06-25"}]}